SUBSCRIBE
SUBSCRIBE
News   FDA

Astellas Pharma Inc. Wins Japan Approval for New Transplant Drug

July 17, 2008 | 
1 min read
TOKYO, July 17 (Reuters) - Astellas Pharma Inc said on Thursday it had won approval to sell a new version of its key transplant drug in Japan, the second major region where it has gained approval although it is facing delays in the United States.
FDA Approvals Asia
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Dorval, Quebec, Canada - September 3, 2021: Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada. Novartis is a global healthcare company based in Switzerland.
Approvals
Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight
November 25, 2025
 · 
3 min read
 · 
Heather McKenzie
Richard Pazdur
FDA
Pazdur Questions Safety, Legality of FDA’s Expedited Drug Approval Programs
November 25, 2025
 · 
2 min read
 · 
Tristan Manalac
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
Regulatory
FDA Frictions Continue as White House Denies Promotion to Makary’s Aide
November 24, 2025
 · 
2 min read
 · 
Tristan Manalac
Symbolic image: Sign 180 degree turn
FDA
FDA Reversals Send UniQure, Biohaven, Capricor, More Into a ‘Tailspin’
November 24, 2025
 · 
7 min read
 · 
Heather McKenzie